US rejects AZ and FibroGen’s anaemia drug roxadustat
FDA has requested an additional clinical trial on the safety of roxadustat
Read More
Tag: roxadustat
AZ’ roxadustat successful in late-stage trial
The trial met its primary efficacy endpoint of a mean change in haemoglobin from baseline averaged over weeks 23-27.
Read More
AZ confirms cardiovascular safety with roxadustat results
The companies will begin discussions with the US Food and Drug Administration (FDA) to prepare for regulatory submission.
Read More
Astellas’ kidney disease drug shows promise in PhIII
A Phase III study assessing Astellas’ roxadustat in patients with chronic kidney disease (CKD) and anaemia who are not receiving dialysis has met its key endpoints.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
